XORTX Therapeutics Inc.
XRTX
$0.45
-$0.02-4.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -19.98% | -26.26% | -19.14% | -2.36% | -3.43% |
| Depreciation & Amortization | -4.27% | -5.46% | -0.38% | 5.71% | -16.18% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.93% | -14.87% | -23.87% | -28.44% | -47.20% |
| Operating Income | 2.93% | 14.87% | 23.87% | 28.44% | 47.20% |
| Income Before Tax | 19.83% | -163.83% | -26.83% | 70.31% | -53.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 19.83% | -163.83% | -26.83% | 70.31% | -53.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.83% | -163.83% | -26.83% | 70.31% | -53.53% |
| EBIT | 2.93% | 14.87% | 23.87% | 28.44% | 47.20% |
| EBITDA | 0.34% | 12.99% | 23.35% | 28.76% | 47.92% |
| EPS Basic | 55.49% | -1,213.33% | -8.07% | 79.15% | -21.23% |
| Normalized Basic EPS | 55.52% | -1,207.08% | -8.02% | 79.15% | -21.24% |
| EPS Diluted | 55.23% | -1,223.33% | -8.16% | 79.02% | -20.48% |
| Normalized Diluted EPS | 55.52% | -1,207.08% | -8.02% | 79.15% | -21.24% |
| Average Basic Shares Outstanding | 64.40% | 52.97% | 46.88% | 52.15% | 45.25% |
| Average Diluted Shares Outstanding | 64.40% | 52.97% | 46.88% | 52.15% | 45.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |